Corpus overview


MeSH Disease

Human Phenotype


    displaying 1 - 3 records in total 3
    records per page

    Acute Pulmonary Embolism HP Pulmonary Embolism MESHD In Non-Hospitalized Covid-19 Patients Referred To CTPA By Emergency Department

    Authors: GERVAISE Alban; BOUZAD Caroline; PEROUX Evelyne; HELISSEY Carole

    doi:10.21203/ Date: 2020-04-29 Source: ResearchSquare

    Objectives: To evaluate the prevalence SERO of acute pulmonary embolism HP pulmonary embolism MESHD (APE) in non-hospitalized COVID-19 patients referred to CT pulmonary angiography (CTPA) by Emergency Department.Methods: From March 14 to April 6, 2020, 72 non-hospitalized patients referred by Emergency Department to CTPA for COVID-19 pneumonia HP pneumonia MESHD were retrospectively identified. Relevant clinical and laboratory data and CT scan findings were collected for each patient. CTPA scans were reviewed by two radiologists to determinate the presence or absence of APE MESHD. Clinical classification, lung involvement of COVID-19 pneumonia HP pneumonia MESHD and CT total severity score were compared between APE group and Non-APE group.Results: APE was identified in 13 (18%) CTPA scans. The mean age TRANS and D-dimer of patients from APE group were higher in comparison with Non-APE group (74.4 vs. 59.6 years, p=0.008 and 7.29 vs. 3.29 µg/ml, p=0.011). There was no significant difference between APE and Non-APE groups concerning clinical type, COVID-19 pneumonia HP pneumonia MESHD lung lesions (ground-glass opacity: 85 vs. 97%; consolidation: 69 vs. 68%; crazy paving: 38% vs. 37%; linear reticulation: 69 vs. 78%), CT severity score (6.3 vs. 7.1, p=0.365), quality of CTPA (1.8 vs. 2.0, p=0.518) and pleural effusion HP pleural effusion MESHD (38% vs. 19%, p=0.146).Conclusions: Non-hospitalized patients with COVID-19 pneumonia HP pneumonia MESHD referred to CT-scan by Emergency Departments are at risk of APE. Presence of APE was not limited to severe or critical clinical type of COVID-19 pneumonia HP pneumonia MESHD.

    18F-FDG PET/CT uptake in COVID-19: case report of a patient with lung metastases MESHD after treatment of nasal cavity malignancy MESHD

    Authors: Hongyan Feng; Lihong Bu

    doi:10.21203/ Date: 2020-04-20 Source: ResearchSquare

    Background: In high COVID-19 prevalence SERO region, COVID-19 disease may be incidental found in non-specific symptoms or asymptomatic TRANS patient with history of tumor MESHD who underwent 18F-FDG-PET/CT for standard oncologic indications.Case presentation: A 51-year-old woman with a 4-year history of adenoid cystic carcinoma of nasal cavity MESHD carcinoma HP of nasal cavity underwent 18F-FDG PET/CT for restaging during COVID-19 outbreak in Wuhan. Pneumonia HP Pneumonia MESHD lesions were characterized by 18F-FDG uptake ground-glass opacities (GGOs) and multifocal high 18F-FDG-avid patchy consolidation, and without lymph node involvement and pleural effusion HP pleural effusion MESHD. Furthermore, multiple 18F-FDG-positive lung and lumbar metastases MESHD were observed. Finally, a diagnosis of COVID-19 was made based on a positive real-time fluorescent polymerase chain reaction (RT-PCR) test of SARS-CoV-2 nucleic acid. Conclusion: The non-specific symptoms or asymptomatic TRANS cancer MESHD patients presenting 18F-FDG-positive GGOs and patchy consolidation lesions in lung may favor COVID-19, who should be quickly SARS-CoV-2 nucleic acid tested and monitored.

    Clinical characterization and chest CT findings in laboratory-confirmed COVID-19: a systematic review and meta-analysis

    Authors: Golnaz Vaseghi; Marjan Mansourian; Raheleh Karimi; Kiyan Heshmat-Ghahdarijani; Sadegh Baradaran Mahdavi; Amirhossein Pezeshki; Behrooz Ataei; Alireza Zandifar; Omid Shafaat; Shaghayegh Haghjoo Javanmard

    doi:10.1101/2020.03.05.20031518 Date: 2020-03-08 Source: medRxiv

    Background: Imagery techniques have been used as essential parts of diagnostic workup for patients suspected for 2019-nCoV infection MESHD, Multiple studies have reported the features of chest computed tomography (CT) scans among a number of 2019-nCoV patients. Method: Study Identification was carried out in databases (PubMed, Embase and Cochrane Library) to identify published studies examining the diagnosis, the 2019 novel coronavirus (2019-nCoV). Heterogeneity among reported prevalence SERO was assessed by computing p-values of Cochrane Q-test and I2-statics. The pooled prevalence SERO of treatment failure was carried out with a fixed effects meta-analysis model, generating the pooled 95% confidence interval. A random-effect model was used to pool the results since this model could incorporate the heterogeneity of the studies and therefore proved a more generalized result. Results: According to the combined results of meta-analysis, the total 55% of corona patients were males TRANS. The mean age TRANS of the patients was 41.31 (34.14, 48.47). Two prevalent clinical symptoms between patients were fever HP fever MESHD, cough HP cough MESHD with prevalence SERO of 85%, and 62%, respectively. Either Ground Glass Opacity GGO or consolidation was seen in 86% but 14% had NO GGO or consolidation. The other rare CT symptoms were pericardial effusion HP, and pleural effusion HP pleural effusion MESHD with 4, 5, 7% prevalence SERO, respectively. The most prevalent event was Either GGO or consolidation in 85% of patients. Conclusion: The most CT-scan abnormality is Either Ground Glass Opacity GGO or consolidation however in few patients none of them might be observed, so trusting in just CT findings will lead to miss some patients.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.